Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease [PDF]
Clinical and Molecular Hepatology, 2018 Background/Aims Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of ...
Saba Sayari +2 more
doaj +2 more sources
An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
Applied Sciences, 2018 Sitagliptin (MK-0431), is a potent oral hypoglycemic drug that is used for treating type 2 diabetes mellitus. However, the short half-life of sitagliptin requires patients to take a high dose of 50 mg twice per day, and the fraction of sitagliptin ...
Afzal Haq Asif +3 more
doaj +2 more sources
Sitagliptin Alleviates Radiation-Induced Kidney and Testis Degeneration in Rats [PDF]
BiomoleculesBackground: Radiation-induced tissue degeneration is the most important side effect of radiotherapy. Sitagliptin with its anti-inflammatory and antioxidant capacity was tested in alleviating the radiation-induced cellular degeneration in kidney and ...
Huseyin Celik +4 more
doaj +2 more sources
Genetic Study on the Effect of the Antidiabetic Drug (Sitagliptin) on DNA and Chromosomes of Human Lymphocyte Culture [PDF]
The Egyptian Journal of Histology, 2021 Background: Diabetes mellitus is a worsening worldwide health problem. It constitutes a major global health concern. Sitagliptin selectively inhibits dipeptidyl peptidase-4 (DPP-4) to manage type 2 diabetes mellitus (T2DM). It regulates the blood glucose
Rania Yassien +4 more
doaj +1 more source
The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Fatty liver disease (FLD) is a disorder related to accumulation of excess fat within the hepatocytes. In this study, the effects of Berberine, a natural compound, and Sitagliptin as a DPP-4 inhibitor, were observed in a rat model of FLD ...
Soraya Mehrdoost +3 more
doaj +1 more source
Maternal sitagliptin treatment attenuates offspring glucose metabolism and intestinal proinflammatory cytokines IL-6 and TNF-α expression in male rats [PDF]
PeerJ, 2020 Increasing evidence shows that maternal overnutrition may increase the risk of diabetes in offspring. We hypothesized that maternal sitagliptin intervention may improve glucose intolerance through gut targeting. Female Sprague-Dawley (SD) rats were fed a
Qian Zhang +7 more
doaj +2 more sources
Identification of sitagliptin binding proteins by affinity purification mass spectrometry
Acta Biochimica et Biophysica Sinica, 2022 Type 2 diabetes mellitus (T2DM) is recognized as a serious public health concern with increasing incidence. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin has been used for the treatment of T2DM worldwide.
Wang Xue-Ning +12 more
doaj +1 more source
Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor. [PDF]
PLoS ONE, 2015 Sitagliptin (SG) increases serum GLP-1 (Glucagon-like peptide-1) through inhibition of the hormone degradation. Resistant starch (RS) induces GLP-1 expression by stimulating L-cells in the intestine.
Felicia Goldsmith +9 more
doaj +1 more source
Frontiers in Endocrinology, 2022 PurposeDipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
Xingchun Wang +6 more
doaj +1 more source
Frontiers in Endocrinology, 2023 BackgroundDiabetes has become a serious global public health problem. With the increasing prevalence of type 2 diabetes mellitus (T2DM), the incidence of complications of T2DM is also on the rise.
Jian-hong Qi +6 more
doaj +1 more source